テキサスにおける多発性硬化症の臨床試験
テキサス内の拠点で、多発性硬化症に関する17件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト(英語)
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Prime Clinical Research, Lewisville
被験者募集中第2相
18歳〜70歳 · 全性別 · 2026/10/01更新 · NCT06782490A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- TG Therapeutics Investigational Trial Site, Austin
- TG Therapeutics Investigational Trial Site, Austin
- TG Therapeutics Investigational Trial Site, Austin
- 他6件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/23更新 · NCT06433752Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- 他2件
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT03816345Delivery of a Culturally Tailored Exercise Training Intervention for Hispanics With Multiple Sclerosis
- The University of Texas Health Science Center at Houston, Houston
被験者募集中
18歳以上 · 全性別 · 2026/09/17更新 · NCT07606742Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- ANESC Research- Site Number : 8400187, El Paso
- North Texas Institute of Neurology & Headache - Plano- Site Number : 8400082, Plano
- North Texas Institute of Neurology & Headache - Plano- Site Number : 8400083, Plano
被験者募集中第3相
18歳〜60歳 · 全性別 · 2026/09/15更新 · NCT07325292Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
- The University of Texas at Dallas, Richardson
被験者募集中
18歳〜65歳 · 全性別 · 2026/09/15更新 · NCT05958381RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Dell Medical School, University of Texas at Austin, Austin
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/09/15更新 · NCT07002034Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
- Local Institution - 0133, El Paso
被験者募集中第3相
10歳〜17歳 · 全性別 · 2026/09/10更新 · NCT06408259Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study
- University of Texas at Austin, Austin
被験者募集中
18歳〜80歳 · 全性別 · 2026/08/17更新 · NCT07759115Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
- UT Southwestern Medical Center (Ophthalmology CRU), Dallas
- Neuro-Eye Clinical Trials, Houston
被験者募集中第3相
18歳〜50歳 · 全性別 · 2026/08/14更新 · NCT07623668A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Carum Research, Dallas
- Saturn Research Solution, Plano
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/07/29更新 · NCT07225504A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
- University of Texas Southwestern Medical Center, Dallas
- ANESC Research, El Paso
- Saturn Research Solutions, Plano
被験者募集中第2相
18歳〜55歳 · 全性別 · 2026/06/15更新 · NCT06735248Care in Multiple Sclerosis (MS)
- Baylor College of Medicine, Houston
被験者募集中観察研究
18歳以上 · 全性別 · 2026/05/05更新 · NCT07011914Non-invasive BCI-controlled Assistive Devices
- The University of Texas at Austin, Austin
被験者募集中健康なボランティア歓迎
18歳〜80歳 · 全性別 · 2026/05/01更新 · NCT05183152Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
- Houston Methodist Hospital, Houston
被験者募集中
18歳以上 · 女性 · 2026/03/23更新 · NCT06072703Multiple Sclerosis Implementation Network (Registry)
- The University of Texas at Austin, Austin
- The University of Texas Health Science Center at Houston (UTHealth Houston), Houston
被験者募集中観察研究
18歳以上 · 全性別 · 2026/02/17更新 · NCT07415824NARCOMS Registry: A Multiple Sclerosis Registry
- UT Southwestern Medical Center, Dallas
被験者募集中観察研究
18歳以上 · 全性別 · 2025/11/13更新 · NCT01018537ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。